Viral Vector-Based Gene Therapy Industry 2025: Major Trends, Influencing Factors & Forecast Overview
Viral Vector-Based Gene Therapy Global Market Report 2025
The Business Research Company's Viral Vector-Based Gene Therapy Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, December 16, 2025 /EINPresswire.com/ -- "The viral vector-based gene therapy market is rapidly evolving, driven by technological advancements and increasing investments in the biopharmaceutical sector. With growing global demand for innovative medical treatments, this market is poised for significant expansion over the coming years. Below, we explore the current market size, growth drivers, key players, and regional trends shaping its future.
Viral Vector-Based Gene Therapy Market Size and Growth Outlook
The market for viral vector-based gene therapy has experienced swift growth recently, with its size rising from $5.77 billion in 2024 to an anticipated $6.77 billion in 2025, marking a compound annual growth rate (CAGR) of 17.4%. This expansion during the historic period has been driven by increased funding towards gene therapy research, expansion in biopharmaceutical manufacturing capacities, a surge in mergers and acquisitions within the gene therapy sector, ramped-up viral vector production facilities, and strong governmental backing for advanced therapies.
Download a free sample of the viral vector-based gene therapy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30431&type=smp
Looking ahead, the market is expected to grow even more rapidly, reaching $12.68 billion by 2029, with a CAGR of 17.0%. This forecasted growth is supported by rising investments in large-scale vector manufacturing, a stronger focus on commercial gene therapy production, greater adoption of automation technologies in vector processing, expansion of global biomanufacturing infrastructures, and enhanced collaboration between biotech firms and contract development and manufacturing organizations (CDMOs). Key trends anticipated to shape the market include advancements in vector design technologies, innovations in delivery methods, progress in large-scale manufacturing techniques, ongoing R&D in next-generation vectors, and improvements targeting safety and efficacy.
Understanding Viral Vector-Based Gene Therapy and Its Medical Role
Viral vector-based gene therapy is a treatment method that uses genetically engineered viruses to deliver therapeutic genes into a patient’s cells, aiming to treat or prevent various diseases. These viral vectors are carefully modified to be safe and incapable of replication, yet efficient at transferring genetic material into the target cells. This approach allows for corrective measures against genetic defects, modulation of gene expression, or stimulation of immune responses, resulting in potentially long-lasting therapeutic benefits.
View the full viral vector-based gene therapy market report:
https://www.thebusinessresearchcompany.com/report/global-viral-vector-based-gene-therapy-market-report
Increasing Prevalence of Genetic Disorders Fuels Market Growth
One significant driver behind the growth of the viral vector-based gene therapy market is the rising prevalence of genetic diseases. These disorders, caused by DNA mutations or changes, can be inherited or arise spontaneously, often impacting health and physiological functions. Enhanced awareness combined with improvements in diagnostic technologies has led to earlier and more precise detection of genetic conditions that were previously undiagnosed.
Viral vector-based gene therapies offer targeted gene delivery that effectively manages inherited disorders by correcting genetic abnormalities in a precise and lasting manner. This capability helps slow disease progression, improves patient outcomes, and enhances quality of life. For example, data from the International Diabetes Federation (IDF) in April 2025 highlights that about 589 million people were living with diabetes in 2024, a figure expected to climb to 853 million by 2050. Such statistics underscore how increasing genetic disease burden is accelerating demand for viral vector therapies.
North America Leads Viral Vector-Based Gene Therapy Market, Asia-Pacific Growing Fastest
In 2024, North America held the largest share of the viral vector-based gene therapy market, reflecting strong regional investments and infrastructure. However, the Asia-Pacific region is projected to be the fastest-growing market during the forecast period, driven by increased healthcare spending, expanding biomanufacturing capabilities, and growing adoption of advanced therapies. The market analysis also includes key regions such as Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of global trends influencing this dynamic sector.
Browse Through More Reports Similar to the Global Viral Vector-Based Gene Therapy Market 2025, By The Business Research Company
Nucleic Acid Based Gene Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report
Genes Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Antiviral Combination Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
